Tsao David sold $2.2M of BLLN

Tsao David (Chief Technology Officer) sold 20,000 shares of BillionToOne, Inc. (BLLN) at an average of $108.15 ($105.56–$110.09, $2.16M total) across 11 trades on 2026-10-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tsao David
Published Oct 7, 2026, 11:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 11:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Bearish
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNBearishLow
01

Why it matters

The disclosed sale may create short‑term downward pressure on BLLN shares.

02

Market read

Insider sale could affect BLLN price action in the near term.

03

What to watch

Potential upcoming milestones or financing that could offset the negative signal.

Relevance 5/10Novelty 8/10Timing: post-market today

Background

SEC Form 4 filing reports an insider transaction by BLLN's CTO.

Company-level read

Ticker impact

$BLLNBearishMedium confidence
Context

CTO Tsao David sold 20,000 shares for $2.16M via a 10b5-1 plan on 2026-10-05.

Expected impact

likely pressure as market prices in insider sell

Evidence & confidence

Sale size is moderate and the insider is a senior officer, suggesting possible concerns.

Market effects

May weigh on technology sector sentiment for similar small‑cap biotech firms.

Limited to U.S. investors tracking BLLN.

Minimal global impact.

Counterpoint

The sale could be routine under a pre‑arranged plan and not reflect underlying fundamentals.

Key entities

  • Tsao David

    Chief Technology Officer of BillionToOne, Inc.

  • BillionToOne, Inc.

    Issuer of ticker BLLN.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.